This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Increasing collaborations among organizations towards drug development enabled by AI
There has been a significant shift in cutting-edge AI technologies at big pharmaceutical companies. Since 2015, there has been a clear change in the public’s image of artificial intelligence, from skepticism to cautious interest to the realization that AI plays a vital role in the new “data-centric” model of innovation. This shift in perception was supported by a number of elements, including: – a flurry of research discoveries and proof-of-concept studies in a variety of AI application use cases; – a number of commercial successes and successfully attained milestones incorporating AI as a key component of research. For instance, in March 2023, Exscientia PLC announced collaboration with Charité – Universitätsmedizin Berlin (Germany) to adopt AI-driven precision medicine platform in haematological cancers. In February 2023, Verily, an Alphabet precision health company, and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) announced that they are collaborating on novel methods for clinical trials looking at therapies for individuals with Major Depressive Disorder (MDD).
Developing interoperability systems is a challenging factor for the market
The capacity of systems and gadgets to communicate and decipher shared data through wired and wireless networks is referred to as interoperability. For all parties involved in the health care ecosystem, including biopharma businesses, it poses a serious challenge. The majority of biopharmaceutical businesses operate across many geographies with numerous diverse IT systems and require access to information from a wide range of IT systems used by healthcare organisations and other partners. The capacity to establish connectivity and communication between devices and IT systems, as well as between data and workflows, is necessary for interoperability. This is done by using consensus standards and protocols to enable secure and transparent data exchange.
The entire biopharma value chain must be improved through the development of interoperable technologies, especially in the area of patient data sharing with consent. Among many other uses, interoperability can assist businesses in communicating with clinicians and patients more effectively, enhancing the supply chain’s ability to track and trace items, enhancing clinical decision support, locating patients, and enhancing drug adherence. To increase workflow efficiency and performance and to eliminate siloes behaviour, interoperability is required.
What Questions Should You Ask before Buying a Market Research Report?
You need to discover how this will impact the AI in Biopharmaceutical market today, and over the next 10 years:
This report tells you TODAY how the AI in Biopharmaceutical market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company.
Segments Covered in the Report
Technology Outlook
Application
End-users
Increasing collaborations among organizations towards drug development enabled by AI
There has been a significant shift in cutting-edge AI technologies at big pharmaceutical companies. Since 2015, there has been a clear change in the public’s image of artificial intelligence, from skepticism to cautious interest to the realization that AI plays a vital role in the new “data-centric” model of innovation. This shift in perception was supported by a number of elements, including: – a flurry of research discoveries and proof-of-concept studies in a variety of AI application use cases; – a number of commercial successes and successfully attained milestones incorporating AI as a key component of research. For instance, in March 2023, Exscientia PLC announced collaboration with Charité – Universitätsmedizin Berlin (Germany) to adopt AI-driven precision medicine platform in haematological cancers. In February 2023, Verily, an Alphabet precision health company, and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) announced that they are collaborating on novel methods for clinical trials looking at therapies for individuals with Major Depressive Disorder (MDD).
Developing interoperability systems is a challenging factor for the market
The capacity of systems and gadgets to communicate and decipher shared data through wired and wireless networks is referred to as interoperability. For all parties involved in the health care ecosystem, including biopharma businesses, it poses a serious challenge. The majority of biopharmaceutical businesses operate across many geographies with numerous diverse IT systems and require access to information from a wide range of IT systems used by healthcare organisations and other partners. The capacity to establish connectivity and communication between devices and IT systems, as well as between data and workflows, is necessary for interoperability. This is done by using consensus standards and protocols to enable secure and transparent data exchange.
The entire biopharma value chain must be improved through the development of interoperable technologies, especially in the area of patient data sharing with consent. Among many other uses, interoperability can assist businesses in communicating with clinicians and patients more effectively, enhancing the supply chain’s ability to track and trace items, enhancing clinical decision support, locating patients, and enhancing drug adherence. To increase workflow efficiency and performance and to eliminate siloes behaviour, interoperability is required.
What Questions Should You Ask before Buying a Market Research Report?
- How is the AI in Biopharmaceutical market evolving?
- What is driving and restraining the AI in Biopharmaceutical market?
- How will each AI in Biopharmaceutical submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each AI in Biopharmaceutical submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading AI in Biopharmaceutical markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the AI in Biopharmaceutical projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of AI in Biopharmaceutical projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the AI in Biopharmaceutical market?
- Where is the AI in Biopharmaceutical market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the AI in Biopharmaceutical market today, and over the next 10 years:
- Our 218-page report provides 90 tables and 137 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the AI in Biopharmaceutical market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI in Biopharmaceutical prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company.
Segments Covered in the Report
Technology Outlook
- Deep Learning
- NLP
- Image Processing
- Other Technologies
Application
- Business Process & Supply Chain
- Drug Discovery
- Medical Imaging & Diagnostics
- Precision Medicine
End-users
- Manufacturers
- Contract Research Organizations
- Academic & Government Research Institutes